We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PsychoGenics Expands Drug Discovery Relationship with Eli Lilly and Company
News

PsychoGenics Expands Drug Discovery Relationship with Eli Lilly and Company

PsychoGenics Expands Drug Discovery Relationship with Eli Lilly and Company
News

PsychoGenics Expands Drug Discovery Relationship with Eli Lilly and Company

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PsychoGenics Expands Drug Discovery Relationship with Eli Lilly and Company"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PsychoGenics Inc. has announced that it has entered into an additional drug discovery agreement with Eli Lilly and Company. Per the agreement, Lilly will supply pre-candidate compounds that PsychoGenics will evaluate using its proprietary drug discovery technologies, for the treatment of neuropsychiatric disorders.

PsychoGenics and Lilly aim to jointly identify drug candidates suitable for clinical development. Upon Lilly's further development of clinical candidates, PsychoGenics would receive research and milestone payments, and royalties.

Dr. Emer Leahy, President and CEO of PsychoGenics, said, "We are delighted to once again work with Lilly and play an integral and expanding role in a successful drug discovery collaboration. We are confident that by combining the complementary strengths and expertise of PsychoGenics and Lilly, we may identify a new generation of treatments for neuropsychiatric disorders.”

PsychoGenics’ technologies combine its broad in vivo behavioral expertise together with recent developments in robotics, computer vision and bio/cheminformatics to evaluate drug candidates for potential utility across the spectrum of neuropsychiatric disease indications.

Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for discontinued compounds as well as early stage compounds including some with novel “first-in-class” mechanisms of action.

Advertisement